Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Assets (2016 - 2025)

Historic Assets for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $270.1 million.

  • Zevra Therapeutics' Assets rose 4101.52% to $270.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $270.1 million, marking a year-over-year increase of 4101.52%. This contributed to the annual value of $178.1 million for FY2024, which is 336.57% up from last year.
  • As of Q3 2025, Zevra Therapeutics' Assets stood at $270.1 million, which was up 4101.52% from $256.3 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Assets peaked at $270.1 million during Q3 2025, and registered a low of $90.4 million during Q1 2021.
  • For the 5-year period, Zevra Therapeutics' Assets averaged around $151.2 million, with its median value being $138.8 million (2021).
  • As far as peak fluctuations go, Zevra Therapeutics' Assets surged by 112443.77% in 2021, and later plummeted by 1520.29% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Assets stood at $132.9 million in 2021, then fell by 13.24% to $115.3 million in 2022, then soared by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then soared by 51.64% to $270.1 million in 2025.
  • Its Assets was $270.1 million in Q3 2025, compared to $256.3 million in Q2 2025 and $172.7 million in Q1 2025.